Phil, a San Francisco, CA-based provider of therapy deployment software for the pharma market, raised $56M in Series D funding.
The round is part of an arrangement for Warburg Pincus to invest up to $100 million. As part of the deal, Fred Hassan, Director at Warburg Pincus, will join Phil’s board of directors. Hassan has a multi-decade career in pharmaceuticals, including roles as CEO of Schering-Plough and Pharmacia, as well as Board roles at Bausch & Lomb, Precigen, Valeant and Avon Products. He currently serves as a Director of Amgen.
The company intends to use the funds to accelerate the development of products while continuing to support the growth of its customers.
Led by Deepak Thomas, Founder and CEO, Phil provides a software therapy deployment platform for manufacturers to control their distribution channels by streamlining and simplifying the complex, distributed workflow spanning patients, prescribers, pharmacies, insurers, and manufacturers.